Colorectal Cancer Clinical Trials

California Pacific CURRENTS: The online journal of CPMC Research Institute

A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer

Description: This randomized phase II trial studies how well veliparib works with combination chemotherapy and radiation therapy in treating patients with rectal cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced)

Investigators

  • NCI - National Cancer Institute

Eligibility Requirements

Male & female subjects, 18 y/o and older, with a diagnosis of adenocarcinoma of the rectum with the major portion of the tumor intact

Status

Please contact site for study status

Contacts

Brenda Eng, 415-600-1775, Email: EngB@cpmcri.org about Study NRG GI002

A Randomized Phase II Study of Irinotecan and Cetuximab With or Without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy

Description: This randomized phase II trial is studying the side effects and how well giving cetuximab and irinotecan hydrochloride with or without ramucirumab work in treating patients with advanced colorectal cancer with progressive disease after treatment with bevacizumab-containing chemotherapy.

 

Investigators

  • NCI - National Cancer Institute

Eligibility Requirements

Male & female subjects, 18 y/o and older, with histologically confirmed adenocarcinoma of the colon or rectum

Status

Please contact site for study status

Contacts

Brenda Eng, 415-600-1775

A Phase 2 Clinical Trial of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Microsatellite High (MSI-H) Colon Cancer

Description: This study is to examine if Nivolumab alone or in combination with Ipilimumab will demonstrate a meaningful objective response rate in patients with recurrent and metastatic colon cancer who also have a specific biomarker in their tumors

Investigators

  • Ari Baron, MD

Eligibility Requirements

Male & female subjects, 18 y/o and older, with histologically confirmed colorectal cancer

Status

Please contact site for study status
 

Contacts

Brenda Eng, 415-600-1775

 

InterAACT - An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin Plus 5-Fluorouracil Versus Carboplatin Plus Weekly Paclitaxel in Patients With Inoperable Locally Recurrent or Metastatic Disease

Description: This randomized phase II trial studies how well cisplatin and fluorouracil work compared with carboplatin and paclitaxel in treating patients with anal cancer that cannot be removed by surgery
 

Investigators

  • NCI - National Cancer Institute

Eligibility Requirements

& female subjects, 18 y/o and older, with histological or cytological confirmation of epidermoid anal carcinoma (includes squamous, basaloid and cloacogenic lesions) from the primary tumor or a newly diagnosed recurrent/metastatic lesion inoperable. Locally recurrent or metastatic disease (tumor resectability should be assessed by a local surgeon or multidisciplinary team)

Status

Please contact site for study status

Contacts

Brenda Eng, 415-600-1775

A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision

Description: The purpose of this study is to compare the effects of the standard treatment of chemotherapy and radiation to chemotherapy using a combination regimen known as FOLFOX, (the drugs 5-fluorouracil (5-FU), oxaliplatin and leucovorin) and selective use of the standard treatment, depending on response to the FOLFOX

Investigators

  • NCI - National Cancer Institute

Eligibility Requirements

Subjects, 18 years and older, who have a diagnosis of rectal adenocarcinoma and radiologically measurable or clinically evaluable disease as defined in the protocol

Status

Please contact site for study status

Contacts

Peter Gasper, 415-600-3472